By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – SeraCare Life Sciences shareholders have approved the $82 million sale of the firm to private equity firm Linden Capital Partners, SeraCare announced today.

Under the terms of the deal, originally announced in February, holders of outstanding shares of SeraCare's common stock will receive $4 per share. The deal is expected to close on Friday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.